U.S. FDA lifts hold on AstraZeneca head and neck cancer trials

LONDON, Nov 22 (Reuters) - U.S. officials have given a green

light for two clinical trials testing AstraZeneca's

cancer immunotherapy drug durvalumab in head and neck cancer to

resume recruiting...

Read more